26 June 2020 - Reblozyl is the first and only erythroid maturation agent to be approved in the European Union, representing a new class of therapy.

Bristol Myers Squibb and Acceleron Pharma today announced that the European Commission has approved Reblozyl (luspatercept) for the treatment of:

• Adult patients with transfusion-dependent anaemia due to very low-, low- and intermediate-risk myelodysplastic syndromes with ring sideroblasts, who had an unsatisfactory response or are ineligible for erythropoietin-based therapy.
• Adult patients with transfusion-dependent anaemia associated with beta thalassaemia.

Read BMS press release